PH vs RXRX · P/E 28, rev $19.85B vs rev $58.8M
Parker-Hannifin Corporation (PH) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
PH currently screens at market cap $91.89B and trailing P/E 27.7. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the PH and RXRX stock pages for the full models.
Not investment advice.